Improving Outcomes in Pancreatic Cancer - touchONCOLOGY
Pharmaceutics | Free Full-Text | A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines
تويتر \ GTG على تويتر: "Ghaneh et al, phase 2 ESPAC-5F trial: Neoadjuvant therapy w/ GEMCAP, FOLFIRINOX or CRT did not increase resection rate over immediate surgery in borderline resectable pancreatic cancer,
Forest plot for toxicity indirect comparisons among combination... | Download Scientific Diagram
The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. - Abstract - Europe PMC
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage | Nature Communications
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer
Study population assigned to treatment from 16 hospitals. For the... | Download Scientific Diagram
Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma - Jong - 2022 - International Journal of Cancer - Wiley Online Library
GTG on Twitter: "Ghaneh et al, phase 2 ESPAC-5F trial: Neoadjuvant therapy w/ GEMCAP, FOLFIRINOX or CRT did not increase resection rate over immediate surgery in borderline resectable pancreatic cancer, but significantly
Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma - Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
Forest plot of all indirect comparisons among combination regimens in... | Download Scientific Diagram
Progression-free survival in advanced pancreatic cancer according to... | Download Scientific Diagram
GTG on Twitter: "Ghaneh et al, phase 2 ESPAC-5F trial: Neoadjuvant therapy w/ GEMCAP, FOLFIRINOX or CRT did not increase resection rate over immediate surgery in borderline resectable pancreatic cancer, but significantly
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection - Wolfe - 2020 - Cancer Medicine - Wiley Online Library
Figure 1 from FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. | Semantic Scholar
Overall survival in advanced pancreatic cancer according to treatment... | Download Scientific Diagram
Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma - Jong - 2022 - International Journal of Cancer - Wiley Online Library
Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis | Scientific Reports
Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic can
Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma - Jong - 2022 - International Journal of Cancer - Wiley Online Library
Neoadjuvant Therapy in Upfront Resectable Pancreatic Cancer | SpringerLink
